Table 1. Patient baseline characteristics.
| Total | BMI≥25(overweight) | BMI<25(non-overweight) | P value | |
| N=2,078 | N=1,412 | N=666 | ||
| Age | 67 (57–75) | 66 (57–75) | 67 (56–76) | 0.66 |
| Male | 1283 (62%) | 949 (67%) | 334 (50%) | <0.001 |
| Metastatic disease | 1180 (57%) | 785 (56%) | 395 (59%) | 0.11 |
| Glucose on ICI initiation, median | 106 (95–124) | 108 (97–127) | 103 (91–118) | <0.001 |
| ICI type | ||||
| Atezolizumab | 18 (1%) | 13 (1%) | 5 (1%) | 0.22 |
| Ipilimumab | 195 (9%) | 121 (9%) | 74 (11%) | |
| Ipilimumab and nivolumab | 635 (31%) | 422 (30%) | 213 (32%) | |
| Nivolumab | 305 (15%) | 220 (16%) | 85 (13%) | |
| Nivolumab and relatlimab | 30 (1%) | 19 (1%) | 11 (2%) | |
| Pembrolizumab | 895 (43%) | 617 (44%) | 278 (42%) | |
| Targeted therapy | ||||
| MEK inhibitors | 23 (1%) | 13 (1%) | 10 (2%) | 0.24 |
| BRAF inhibitors | 29 (1%) | 16 (1%) | 13 (2%) | 0.14 |
| Underlying comorbidities | ||||
| T2DM | 215 (10%) | 184 (13%) | 31 (5%) | <0.001 |
| Hypertension | 875 (42%) | 666 (47%) | 209 (31%) | <0.001 |
| Hyperlipidemia | 734 (35%) | 558 (40%) | 176 (26%) | <0.001 |
| Heart failure | 99 (5%) | 76 (5%) | 23 (3%) | 0.054 |
| Ischemic heart disease | 11 (1%) | 9 (1%) | 2 (0%) | 0.32 |
| Chronic kidney disease | 124 (6%) | 91 (6%) | 33 (5%) | 0.18 |
| COPD | 103 (5%) | 75 (5%) | 28 (4%) | 0.28 |
| Cardiovascular and metabolic medications | ||||
| Beta-blocker | 461 (22%) | 342 (24%) | 119 (18%) | 0.001 |
| Diuretics | 191 (9%) | 136 (10%) | 55 (8%) | 0.31 |
| Calcium channel blocker | 261 (13%) | 192 (14%) | 69 (10%) | 0.038 |
| Aspirin | 249 (12%) | 177 (13%) | 72 (11%) | 0.26 |
| Renin-angiotensin system inhibitor | 384 (18%) | 300 (21%) | 84 (13%) | <0.001 |
| Metformin | 121 (6%) | 102 (7%) | 19 (3%) | <0.001 |
| Insulin | 87 (4%) | 76 (5%) | 11 (2%) | <0.001 |
| Statin | 452 (22%) | 343 (24%) | 109 (16%) | <0.001 |
BMI unit: kg/m2.
Glucose unit: mg/dL.
BMIbody mass indexCOPDchronic obstructive pulmonary diseaseICIimmune checkpoint inhibitorT2DMtype 2 diabetes mellitus